Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.

The Journal of toxicological sciences ·Vol. 21 ·No. 5 ·1996-12-00 ·Pages 309-16

Sugiyama Y, Iwatsubo T, Ueda K, Ito K

Abstract

暂无摘要

MeSH Terms

Drug Design Drug Interactions Drug-Related Side Effects and Adverse Reactions Humans Pharmaceutical Preparations/metabolism Pharmacokinetics Product Surveillance, Postmarketing Risk Assessment

Chemicals

Pharmaceutical Preparations

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Sugiyama Y

Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.

Iwatsubo T

Ueda K

Ito K

Article Info

Journal

The Journal of toxicological sciences

Abbr.

J Toxicol Sci

ISSN

0388-1350

DOI

10.2131/jts.21.5_309

Published

1996-12-00

Pages

309-16

Language

English

Region

Japan

NLM ID

7805798

Subset

External Links

PubMed source DOI: 10.2131/jts.21.5_309 View journal details

Analysis Services

Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.

Contact

WeChat Official Account